Invasive Aspergillosis Therapeutics Market Report 2026

Invasive Aspergillosis Therapeutics Market Overview

• Invasive Aspergillosis Therapeutics market size has reached to $1.13 billion in 2025 • Expected to grow to $1.42 billion in 2030 at a compound annual growth rate (CAGR) of 4.5% • Growth Driver: Fungal Infections Propel The Growth Of The Market • Market Trend: Cost-Effective Solutions In Fungal Infections • North America was the largest region in 2025.

What Is Covered Under Invasive Aspergillosis Therapeutics Market?

Invasive aspergillosis therapeutics refers to treatments used to manage severe Aspergillus infections, primarily in immunocompromised patients. These include antifungal medications such as voriconazole, amphotericin B, and echinocandins, which target fungal growth and infection spread. Adjunctive therapies, such as immunomodulators and surgical interventions, may be considered in refractory cases. The main drug classes for invasive aspergillosis therapeutics are azoles, echinocandins, polyenes, and others. Azoles are a class of antifungal drugs that inhibit the synthesis of ergosterol, an essential component of fungal cell membranes, used to treat infections. These therapeutics are administered through oral and intravenous routes and are distributed across various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.

What Is The Invasive Aspergillosis Therapeutics Market Growth Forecast?

The invasive aspergillosis therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.42 billion in 2030 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to development of novel antifungal drug classes, growing antifungal resistance awareness, expansion of intensive care units globally, increasing fungal infection surveillance programs, improved access to specialty antifungal therapies. Major trends in the forecast period include rising adoption of first-line azole antifungal therapies, growing use of combination antifungal treatment regimens, increasing focus on early diagnosis in immunocompromised patients, expansion of intravenous antifungal use in critical care settings, growing demand for broad-spectrum and lipid-based formulations.

What Is The Driver Of The Invasive Aspergillosis Therapeutics Market?

The rising prevalence of fungal infections is expected to propel the growth of the invasive aspergillosis therapeutics market going forward. Fungal infections refer to diseases caused by fungi invading tissues, often affecting skin, nails, or internal organs. The prevalence of fungal infections is growing due to increasing immunocompromised populations, climate change, antimicrobial resistance, and global travel exposure. Invasive aspergillosis therapeutics are helpful for fungal infections by utilizing antifungal agents like triazoles, echinocandins, and polyenes, which help inhibit fungal growth, reduce disease progression, and improve survival rates, making early diagnosis crucial for managing other invasive fungal infections with similar pathogenic mechanisms. For instance, in January 2024, according to the Center for Infectious Disease Research and Policy, a US-based public health company, in 2023, over 6.55 million people are affected by invasive fungal infections annually, leading to more than 3.75 million deaths, with 2.55 million directly attributable to these diseases, significantly higher than previous year estimates. Therefore, the rising prevalence of fungal infections is driving the growth of the invasive aspergillosis therapeutics industry.

Key Players In The Global Invasive Aspergillosis Therapeutics Market

Major companies operating in the invasive aspergillosis therapeutics market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Gilead Sciences, Astellas Pharma Inc., Shionogi & Co. Ltd, Hikma Pharmaceuticals, Cipla Ltd., Mylan Pharmaceuticals Inc., Basilea Pharmaceutica International Ltd., Pulmocide Ltd., F2G Ltd., Hetero Healthcare, Eugia Pharma, SCYNEXIS Inc., Biosergen AB.

Global Invasive Aspergillosis Therapeutics Market Trends and Insights

Major companies operating in the invasive aspergillosis therapeutics market are emphasizing effective treatments, including generic drugs, to improve accessibility, lower costs, and enhance patient outcomes. Generic drugs contain the same active ingredients, dosage, safety, strength, administration route, quality, and efficacy as brand-name counterparts but are generally more affordable. For instance, in September 2023, BDR Pharmaceutical, an India-based pharma company, announced the launch of its innovative generic product, Zisavel capsules, designed to treat invasive aspergillosis and mucormycosis. Zisavel belongs to the isavuconazole class of azole antifungals and provides a crucial therapeutic option for these serious fungal infections. The capsules are available in a 100 mg dosage and are positioned as the first-line treatment for both conditions. Priced at Rs. 7,992 for a pack of seven capsules, Zisavel is approximately one-third the cost of the current innovator therapy, making it a cost-effective alternative for patients.

What Are Latest Mergers And Acquisitions In The Invasive Aspergillosis Therapeutics Market?

In September 2024, Basilea Pharmaceutica Ltd, a Switzerland-based commercial-stage biopharmaceutical company, entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of novel antifungal and antibacterial therapies. With this partnership, Basilea and BARDA aim to progress Basilea’s clinical-stage antifungal candidates, including fosmanogepix and BAL2062, toward regulatory approval, strengthen treatment options for severe invasive fungal infections such as invasive aspergillosis, support preparedness against resistant pathogens, and enhance long-term development sustainability through milestone-based non-dilutive funding. BARDA is a U.S.-based federal agency under the Department of Health and Human Services that supports the advanced development of medical countermeasures for public health emergencies.

What Defines the Invasive Aspergillosis Therapeutics Market?

The invasive aspergillosis therapeutics market consists of revenues earned by entities by providing services such as hospital & clinical treatment services, diagnostic testing and screening, telemedicine, and remote consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive aspergillosis therapeutics market also includes sales of antifungal medications, adjunctive and supportive therapies, and prophylactic therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Invasive Aspergillosis Therapeutics Market Report 2026?

The invasive aspergillosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the invasive aspergillosis therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.